PRESS RELEASE

The HelixPharma team is proud to announce the market introduction of a brand new product, based on its innovative and licensed primary product: GlicoPro®. Thanks to the long lasting research relationship between Ferrara’s University Spin-Off/Innovative Start-Up HelixPharma, and FB Vision Spa (Company leader in the ophthalmic preparation and production field, based in San Beedetto del Tronto), a new unique ophthalmic product was designed.

That has brough the two parts on 10/05/2021 in launching officially on market the first eyedrop able to treat the Dry Eyes Syndrome (DES), containing GlicoPro® as main active.

The latter active principle was fine-tuned by the Italian Start-Up, and it embraces all the biological typical characteristics of HelixComplex, another licensed component, which is the result of the local supply chain and extraction method typical of HelixPharma.

These two companies combined their strengths in order to develop a new product, whose efficacy and safety were tested and corroborated by two Ferrara’s University scientific specialists: Microbiology Full Professor Roberta Rizzo and Organic Chemistry Full Professor Claudio Trapella.

Among all the properties that this product claims, those that deserved to be mentioned are the remarkable mucoadesive one, which is possible thanks to the remarkable presence of sulfurated mucopolysaccharides, compounds able to modify the rheological properties of the product, and the pH values almost identical to the ocular surface one.

This latest ability is capable to improve the lasting time of the product over the eye surface, promoting tissue repairing process; moreover the presence of Ophiorphine, an opioid peptide detected inside HelixComplex and identified also inside GlycoPro®, allows a modulatory effect on eye pain, a target that hadn’t been achieved in any treatment of DES, so far.